Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mangoceuticals, Inc. (MGRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Mangoceuticals describes itself as a Texas corporation whose common stock trades on the Nasdaq Capital Market, and its Form 8-K filings and related documents offer detailed insight into material agreements, financings, and corporate events.
Recent Mangoceuticals filings include Form 8-K reports on private placements of common stock, registered direct offerings and concurrent private placements of warrants, conversions of preferred stock and convertible notes into common stock, and warrant exercises. The company has also filed 8-Ks describing a lease agreement for office space in Dallas, Texas, a separation agreement with a former chief operating officer, and the resignation of a president and director. Other filings outline amendments to promissory notes, issuance of warrants, and the use of an equity line of credit arrangement.
Mangoceuticals’ SEC reports also document its entry into, and subsequent mutual rescission of, a Master Distribution Agreement for exclusive licensing and distribution rights to the nutraceutical Diabetinol in the United States and Canada. Additional 8-Ks reference company press releases about topics such as GLP-1–related programs and other corporate announcements, which are incorporated by reference as exhibits.
On this page, you can review Mangoceuticals’ 8-K filings and other available forms to understand how the company structures financings, manages key agreements, and reports significant events. AI-powered summaries on Stock Titan help explain the main points of lengthy documents, highlight important terms such as conversion prices or warrant conditions, and point out sections related to capital structure and obligations. Real-time updates from EDGAR, along with access to historical filings, allow investors and researchers to monitor MGRX’s regulatory history, governance changes, and transaction activity in a single, organized view.
Mangoceuticals, Inc. reported new data on its proprietary antiviral compound MGX-0024 for use in poultry. In three commercial field trials in India covering approximately 29,000 broiler chickens, birds receiving MGX-0024 in drinking water had zero respiratory-related mortality, despite historical and neighboring flock data suggesting about 50% respiratory-related deaths.
A separate controlled government study using a highly pathogenic H5N1 strain found that birds pre-treated with MGX-0024 for 48 hours showed up to a 60% reduction in mortality versus untreated controls, longer time to death, and limited viral shedding. The company emphasizes these results are preliminary, subject to further validation, regulatory review, and not yet approved for veterinary use.
Mangoceuticals, Inc. reported early traction for its newly launched all-inclusive injectable testosterone replacement therapy (TRT) program, priced at $99 per month. The offer covers doctor visits, lab work and prescribed medication, delivered via the company’s telemedicine platform under the MangoRx brand.
The company highlighted that month-over-month sales for the injectable TRT program have risen 336% since its mid-December launch, while customer acquisition costs declined 54%. Management views TRT as the primary growth focus and plans to expand both injectable and oral offerings as part of a broader men’s health platform.
Mangoceuticals, Inc. reported that on February 4, 2026 it received a deficiency notice from Nasdaq because its common stock bid price had closed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar day grace period, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. Nasdaq’s notice does not immediately affect the listing or trading of the stock, and Mangoceuticals plans to monitor its share price and consider options to address the deficiency.
Mangoceuticals, Inc. is registering 2,640,178 shares of common stock for resale by existing investors. The shares consist of 1,930,502 shares issuable upon exercise of warrants with a $1.4245 per share exercise price and 709,676 already issued shares that were sold at $1.55 per share to accredited investors.
The company is not selling any shares in this offering and will not receive proceeds from resale by the selling stockholders; it will receive cash only if the warrants are exercised, which it plans to use for general working capital. Mangoceuticals operates the MangoRX telehealth platform, offering compounded men’s wellness products and an FDA‑approved oral testosterone therapy, and relies on related-party pharmacy Epiq Scripts for compounding and fulfillment. Its common stock trades on Nasdaq under the symbol MGRX, with a last reported price of $0.537 per share on January 22, 2026.
Mangoceuticals, Inc. has filed a Form S-1 registering up to 2,640,178 shares of common stock for resale by existing stockholders. The shares consist of 1,930,502 shares issuable upon exercise of common stock purchase warrants at an exercise price of $1.4245 per share and 709,676 already issued shares that were sold to accredited investors at $1.55 per share. The company is not selling any shares itself in this offering and will not receive proceeds from stockholder resales, but would receive cash if holders exercise the warrants, which it plans to use for general working capital. The selling stockholders may sell their shares over time in various types of public or private transactions. Mangoceuticals’ common stock trades on Nasdaq under the symbol “MGRX”, and the last reported price on January 12, 2026 was $0.785 per share.
Mangoceuticals, Inc. reported an insider stock transaction by its Chief Financial Officer. On 12/15/2025, the CFO sold 3,333 shares of the company’s common stock at a price of $1.1653 per share. After this sale, the CFO beneficially owned 120,000 shares, held directly. The filing reflects a routine update of the officer’s ownership position and does not list any derivative securities transactions.
Mangoceuticals, Inc. director reports stock sale in Form 4 filing. A board member of Mangoceuticals, Inc. (MGRX) disclosed the sale of 125,000 shares of common stock on 11/19/2025, reported under transaction code "S" for a sale. The weighted average sale price was $1.223 per share.
These shares were sold in multiple trades at prices ranging from $1.195 to $1.2465 per share. Following this transaction, the reporting person beneficially owns 3,334 shares of Mangoceuticals common stock in direct ownership.
Mangoceuticals, Inc. (MGRX) filed Amendment No. 1 to its Q2 2025 Form 10‑Q to correct the Exhibit 32.1 hyperlink, add Item 408(a) disclosures, and include related XBRL tagging. The amendment is presented as of the original filing date and does not otherwise update prior disclosures.
For the quarter ended June 30, 2025, revenue was $168,109 with a net loss of $5,415,820. For the first half of 2025, revenue totaled $277,415, gross profit $152,012, and net loss $10,255,309. Operating expenses for the first half were $10,273,696, including $4,165,924 of stock‑based compensation. Cash and cash equivalents were $101,019 at June 30, 2025. Shares outstanding were 10,535,791 as of August 14, 2025.
The balance sheet reflects $20,694,893 of net intangible assets (acquired patents and license) and total stockholders’ equity of $19,243,064 at June 30, 2025. The previously disclosed 1‑for‑15 reverse stock split effective October 16, 2024 has been retroactively reflected throughout.
Mangoceuticals, Inc. (MGRX) filed a Form 8-K announcing it issued a press release titled “Mangoceuticals Provides Clarification Regarding Availability of Branded GLP,” clarifying a prior press release issued on the same day.
The company furnished the press release as Exhibit 99.1, which is incorporated by reference into the filing. The disclosure is presented under Item 8.01 – Other Events, with no additional transactions or financial results included in this report.